Sort
21,453 grants matching “tuberculosis”
GHESKIO HIV Clinical Trial Unit
$1,446,966Jean William Pape · Gheskio Center · U01 · FY2008 · AI
PItt-Ohio State-Georgetown Clinical Trials Unit
$1,446,339John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2015 · AI
The International Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Center
$1,445,111Jeffrey H Samet · Boston Medical Center · P01 · FY2021 · AA
Experimental Animal Models of TB: Chemotherapeutics and Imaging
$1,444,144Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Development Of New Chemotherapeutics For Tuberculosis
$1,444,144Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
GRANT APPLICATION FOR 2010 TUBERCULOSIS ELIMINATION FOR WASHINGTON STATE
$1,442,293Mark Aubin · Washington State Department Of Health · U52 · FY2012 · PS
Molecular Analysis of Tuberculosis Immunity
$1,442,274William Robert Jacobs · Albert Einstein College Of Medicine · P01 · FY2009 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENT, ILLINOIS OUTSIDE O
$1,441,774Fredrick Echols · Illinois State Dept Of Public Health · U52 · FY2014 · PS
COLORADO ADULT AIDS CLINICAL TRIALS UNIT
$1,440,022University Of Colorado Denver · U01 · FY2004 · AI
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine
$1,439,101Richard Malley · Boston Children'S Hospital · R01 · FY2018 · AI
Caribbean, Central and South America network for HIV epidemiology (CCASnet)
$1,437,731Catherine C McGowan · Vanderbilt University · U01 · FY2011 · AI
ADULT AIDS CLINICAL TRIAL UNIT
$1,436,931University Of Texas Medical Br Galveston · U01 · FY2003 · AI
Viable but Nonculturable Mtb
$1,436,684Carl F Nathan · Weill Medical Coll Of Cornell Univ · U19 · FY2019 · AI
RP4: Harnessing autophagy to treat tuberculosis
$1,435,095Michael Shiloh · Ut Southwestern Medical Center · U19 · FY2022 · AI
T cell recognition of the MR1 presented microbial metabolome
$1,434,057Erin June Adams · University Of Chicago · R01 · FY2019 · AI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,432,109Zachary David Aron · Microbiotix, Inc · R01 · FY2017 · AI
Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis
$1,430,463Antonino None Catanzaro · University Of California, San Diego · U01 · FY2013 · AI
Pharmacology Core
$1,428,749Vidmantas Petraitis · Hackensack University Medical Center · U19 · FY2025 · AI
Vaccines for Extensively Drug Resistant Tuberculosis
$1,427,671William Robert Jacobs · Albert Einstein College Of Medicine · R01 · FY2012 · AI
Innate inflammatory responses during pulmonary infections
$1,427,583Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
RP1: Targeting Beclin 1 complexes for broad-spectrum anti-infective therapeutics
$1,425,661Beth C Levine · Ut Southwestern Medical Center · U19 · FY2020 · AI
GHESKIO HIV Clinical Trial Unit
$1,425,181Jean William Pape · Gheskio Center · UM1 · FY2014 · AI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis
$1,424,115Susan E Dorman · Johns Hopkins University · R01 · FY2017 · AI
Gerome Wide Association Study of Bacterial Determinants of Clinical Response in Tuberculosis
$1,423,701Megan B Murray · Harvard Medical School · U19 · FY2021 · AI
The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center
$1,423,003Jeffrey H Samet · Boston Medical Center · P01 · FY2023 · AA